Physician profile
Kimberly D Roller
NPI 1457544868
$2,349.72
in general payments reported to CMS, 2019-2025
24 companies · $424 in 2025
The $424 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $543 · 2021: $173 · 2022: $98.48 · 2023: $265 · 2024: $404 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,093.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,092.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $654.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $345.40 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $273.15 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $210.94 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $137.04 | 2019-2021 | |
| Amgen INC. | $121.40 | 2019-2020 | |
| Pfizer INC. | $103.59 | 2019-2025 | |
| Astellas Pharma US INC | $75.49 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.11 | 2020-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $49.90 | 2020 | |
| Sanofi-Aventis U.S. LLC | $44.12 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.11 | 2024-2025 | Xifaxan |
| Allergan, INC. | $32.07 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.44 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $30.45 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $28.07 | 2021-2025 | Eliquis |
| Lundbeck LLC | $22.58 | 2024 | Vyepti |
| Inogen, INC. | $16.30 | 2024 | |
| Dynavax Technologies Corporation | $15.51 | 2025 | Heplisav-B |
| Exact Sciences Corporation | $13.80 | 2025 | The Cologuard Plus Collection Kit |
| Teva Pharmaceuticals USA, INC. | $12.56 | 2020 | |
| Abbott Laboratories | $12.30 | 2021 | |
| Merck Sharp & Dohme LLC | $11.82 | 2020 | |
| Phathom Pharmaceuticals, INC. | $9.42 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Roller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.